Literature DB >> 2068531

T-cell responses to fractionated antigens of Mycobacterium w, a candidate anti-leprosy vaccine, in leprosy patients.

A Yadava1, N R Suresh, S A Zaheer, G P Talwar, R Mukherjee.   

Abstract

Mycobacterium w, an atypical cultivable mycobacterium, is undergoing phase III clinical trials as a vaccine against leprosy in India. It has brought about lepromin conversion and histopathological upgradation in a significant number of patients studied so far. It is important to identify antigens of M. w that trigger T-cell responses in leprosy patients vaccinated with this organism. In the present study the peripheral T-cell repertoire of 12 M. w-vaccinated leprosy patients, 10 unimmunized leprosy patients, 8 tuberculoid and 5 healthy contacts was analysed with fractionated antigens of M. w. The lepromatous leprosy patients who are in general anergic to antigens of M. leprae did not respond to antigens of M. w. However, peripheral blood mononuclear cells obtained from leprosy patients who had been vaccinated with M. w responded to many antigens. These responses were frequently directed against low molecular weight entities of 14-45 kDa. T cells from tuberculoid leprosy patients and healthy contacts also responded predominantly to a number of low molecular weight antigens of M. w. The study also identified an immunodominant 28-31 kDa antigenic fraction carrying T- as well as B-cell activating determinants.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2068531     DOI: 10.1111/j.1365-3083.1991.tb01517.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  8 in total

1.  Molecular and immunological analyses of the Mycobacterium avium homolog of the immunodominant Mycobacterium leprae 35-kilodalton protein.

Authors:  J A Triccas; N Winter; P W Roche; A Gilpin; K E Kendrick; W J Britton
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

2.  An immunodominant 30-kDa antigen of a candidate anti-leprosy vaccine, Mycobacterium w, shares T and B cell determinants with M. leprae and M. tuberculosis.

Authors:  A Yadava; R Mukherjee
Journal:  Med Microbiol Immunol       Date:  1993-11       Impact factor: 3.402

3.  Characterization and evaluation of the Moraxella catarrhalis oligopeptide permease A as a mucosal vaccine antigen.

Authors:  Min Yang; Antoinette Johnson; Timothy F Murphy
Journal:  Infect Immun       Date:  2010-12-06       Impact factor: 3.441

Review 4.  A review of the BCG vaccine and other approaches toward tuberculosis eradication.

Authors:  Thomas Cho; Christopher Khatchadourian; Huy Nguyen; Yash Dara; Shuna Jung; Vishwanath Venketaraman
Journal:  Hum Vaccin Immunother       Date:  2021-03-26       Impact factor: 3.452

5.  Mycobacterium indicus pranii supernatant induces apoptotic cell death in mouse peritoneal macrophages in vitro.

Authors:  Rajeev Kumar Pandey; Kunal H Bhatt; Yogesh Dahiya; Ajit Sodhi
Journal:  PLoS One       Date:  2011-02-11       Impact factor: 3.240

6.  Molecular analysis of a leprosy immunotherapeutic bacillus provides insights into Mycobacterium evolution.

Authors:  Niyaz Ahmed; Vikram Saini; Saurabh Raghuvanshi; Jitendra P Khurana; Akhilesh K Tyagi; Anil K Tyagi; Seyed E Hasnain
Journal:  PLoS One       Date:  2007-10-03       Impact factor: 3.240

7.  Polyphasic taxonomic analysis establishes Mycobacterium indicus pranii as a distinct species.

Authors:  Vikram Saini; Saurabh Raghuvanshi; Gursaran P Talwar; Niyaz Ahmed; Jitendra P Khurana; Seyed E Hasnain; Akhilesh K Tyagi; Anil K Tyagi
Journal:  PLoS One       Date:  2009-07-16       Impact factor: 3.240

8.  Efficacy of Mycobacterium indicus pranii immunotherapy as an adjunct to chemotherapy for tuberculosis and underlying immune responses in the lung.

Authors:  Ankan Gupta; Farhan J Ahmad; Faiz Ahmad; Umesh D Gupta; Mohan Natarajan; Vishwamohan Katoch; Sangeeta Bhaskar
Journal:  PLoS One       Date:  2012-07-26       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.